Dr. Jonathan S. Bleeker, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Iowa, Rj & L Carver College of Medicine (2005)
- Years since graduation
- 21
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 496
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Medical school: University of Iowa, Rj & L Carver College of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
SD license 8325 · MN license 52164 · MN license 104308 -
Internal Medicine Physician
VA license 0101244302 -
Student in an Organized Health Care Education/Training Program
VA license 0116017474
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Sanford Usd Medical Center Sioux Falls, SD
- Sanford Worthington Medical Center Worthington, MN
- Sanford Luverne Medical Center Luverne, MN
- Orange City Area Health System Orange City, IA
- Winner Regional Healthcare Center - Cah Winner, SD
Medical groups
- Sanford Medical Center (857 clinicians)
- Sanford Health Network (351 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 496
- Services billed
- 2,049
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 409 | 169 |
| Established patient office or other outpatient visit, 30-39 minutes | 345 | 219 |
| Established patient office or other outpatient visit, 20-29 minutes | 172 | 153 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 55 | 39 |
| New patient office or other outpatient visit, 45-59 minutes | 35 | 35 |
| New patient office or other outpatient visit, 60-74 minutes | 34 | 34 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 24 | 18 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Sioux Falls, SD | 108 |
| Dexamethasone Other prescribers in Sioux Falls, SD | 101 |
| Revlimid (lenalidomide) | 88 |
| Prednisone Other prescribers in Sioux Falls, SD | 73 |
| Acyclovir Other prescribers in Sioux Falls, SD | 70 |
| Prochlorperazine Maleate Other prescribers in Sioux Falls, SD | 59 |
| Abiraterone Acetate | 51 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Sioux Falls, SD | 49 |
| Ibrance (palbociclib) | 25 |
| Calquence (acalabrutinib maleate) | 25 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 2 payments worth $50.27 in total to this clinician.
| Pfizer Inc. | $26.00 |
|---|---|
| E.r. Squibb & Sons, L.l.c. | $24.27 |
| Education | $26.00 |
|---|---|
| Food and Beverage | $24.27 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Jul 28, 2025 | Education PADCEV · ONCOLOGY · in-kind | $26.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $6,094 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physician s Choice in 3L Advanced,Metastatic Gastroesophageal Adenocarcinoma Gastric Adenocarcinom…
Merck Sharp & Dohme LLC - A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians' Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced,Metastatic Adenocarcinoma and Squamous Cell Ca…
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.